Monalizumab

CAS No. 1228763-95-8

Monalizumab( —— )

Catalog No. M36667 CAS No. 1228763-95-8

Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 666 Get Quote
5MG 938 Get Quote
10MG 1311 Get Quote
25MG 1822 Get Quote
50MG 2548 Get Quote
100MG 3357 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Monalizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Monalizumab is a novel immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A).
  • Description
    Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
  • In Vitro
    ——
  • In Vivo
    Animal Model:immunodeficient mice xenografted with Cal-27 HLA-E high tumor cellDosage:50?μg, together with 8?millions of activated NK cells Administration:intratumoral injections Result:Shows a synergestic antitumor effect.Enhanced NK-cell killing, and induces lysis of tumor cells.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    Chk
  • Recptor
    Chk | IFNAR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1228763-95-8
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Thorbald van Hall, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J Immunother Cancer. 2019 Oct 17;7(1):263.?
molnova catalog
related products
  • Tuvusertib

    Tuvusertib (M1774) is an orally available ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor (Ki< 1 μΜ) with selective and potentially antitumor activity.

  • CHIR-124

    CHIR-124 is a potent, selective Chk1 inhibitor with in vitro IC50 of 0.3 nM.

  • SB-218078

    A potent inhibitor of Chk1 that blocks phosphorylation of cdc25 with IC50 of 15 nM.